Detection of SARS-CoV-2-Specific Humoral and Cellular Immunity in COVID-19 Convalescent IndividualsHighlights d SARS-CoV-2-specific antibodies are detected in COVID-19 convalescent subjects d Most COVID-19 convalescent individuals have detectable neutralizing antibodies d Cellular immune responses to SARS-CoV-2 are found in COVID-19 convalescent subjects d Neutralization antibody titers correlate with the numbers of virus-specific T cells.

Single-cell RNA sequencing (scRNA-seq) technologies are poised to reshape the current cell-type classification system. However, a transcriptome-based single-cell atlas has not been achieved for complex mammalian systems. Here, we developed Microwell-seq, a high-throughput and low-cost scRNA-seq platform using simple, inexpensive devices. Using Microwell-seq, we analyzed more than 400,000 single cells covering all of the major mouse organs and constructed a basic scheme for a mouse cell atlas (MCA). We reveal a single-cell hierarchy for many tissues that have not been well characterized previously. We built a web-based "single-cell MCA analysis" pipeline that accurately defines cell types based on single-cell digital expression. Our study demonstrates the wide applicability of the Microwell-seq technology and MCA resource.

No abstract

It has come to our attention that in preparing the final version of this paper, we inadvertently misspelled the first name of an author Ziming Zhou as ''Zimin Zhou''. In addition, we have made two errors in describing the reagents in the STAR Methods. First, under the subheading of ''Synthesis of barcoded beads'' in the Method Details section, the supplier of the magnetic beads coated with carboxyl groups should be Suzhou Knowledge & Benefit Sphere Tech. Co., Ltd. (diameter 20-25 mm, http://www.kbspheretech. com/), instead of Zhiyi. Second, under the subheading of ''Cell collection and lysis'' in the Method Details section, the concentration of Tris-HCL for the cold lysis buffer should be 0.1 M, instead of 1 M. These errors have been corrected online, and we apologize for any confusions we may have caused.

The past decades have witnessed significant efforts toward the development of three-dimensional (3D) cell cultures as systems that better mimic in vivo physiology. Today, 3D cell cultures are emerging, not only as a new tool in early drug discovery but also as potential therapeutics to treat disease. In this review, we assess leading 3D cell culture technologies and their impact on drug discovery, including spheroids, organoids, scaffolds, hydrogels, organs-on-chips, and 3D bioprinting. We also discuss the implementation of these technologies in compound identification, screening, and development, ranging from disease modeling to assessment of efficacy and safety profiles.